Cancer Immunotherapy Meets Oncology
In Honor of Christoph Huber
Page
%P
-
Article
The landscape of T cell antigens for cancer immunotherapy
The remarkable capacity of immunotherapies to induce durable regression in some patients with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As checkpoint-blockade therapy ...
-
Article
Open AccessLocal radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer
Human papilloma virus (HPV) infection is a causative agent for several cancers types (genital, anal and head and neck region). The HPV E6 and E7 proteins are oncogenic drivers and thus are ideal candidates for...
-
Article
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-ref...
-
Chapter
Personalized Neo-Epitope Vaccines for Cancer Treatment
After more than a century of efforts to establish cancer immunotherapy in clinical practice, the advent of checkpoint inhibition (CPI) therapy was a critical breakthrough toward this direction (Hodi et al. in ...
-
Article
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma
The additional author support information was erroneously omitted from the Supplementary Information. This has been corrected online.
-
Article
Actively personalized vaccination trial for newly diagnosed glioblastoma
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a hig...
-
Article
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
The authors report the first-in-human application of personalized neo-antigen RNA vaccines in patients with melanoma.
-
Protocol
Discovery and Subty** of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome
Cancer accumulates 10s to 1000s of genomic mutations of which a fraction is immunogenic and may serve as an Achilles’ heel of tumor cells. Mutation-specific T cells can recognize these antigens and destroy mal...
-
Protocol
The European Regulatory Environment of RNA-Based Vaccines
A variety of different mRNA-based drugs are currently in development. This became possible, since major breakthroughs in RNA research during the last decades allowed impressive improvements of translation, sta...
-
Article
Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice
Intradermal administration of antigen-encoding RNA has entered clinical testing for cancer vaccination. However, insight into the underlying mechanism of RNA uptake, translation and antigen presentation is sti...
-
Article
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
The development of a nanoparticle RNA vaccine is reported that preferentially targets dendritic cells after systemic administration, and is shown to provide durable interferon-α-dependent antigen-specific immu...
-
Protocol
FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines
Intranodal immunization with antigen-encoding naked mRNA has proven to be an efficacious and safe approach to induce antitumor immunity. Thanks to its unique characteristics, mRNA can act not only as a source ...
-
Article
Erratum: Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Nature 520, 692–696 (2015); doi:10.1038/nature14426 In this Letter, there were minor formatting errors in the poly‐neo‐epitope RNA in Fig. 3a, which occurred during the production process; this figure has been...
-
Article
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
The authors show that a large fraction of tumour mutations is immunogenic and predominantly recognized by CD4+ T cells; they use these data to design synthetic messenger-RNA-based vaccines specific against tumour...
-
Article
Open AccessMutated tumor alleles are expressed according to their DNA frequency
The transcription of tumor mutations from DNA into RNA has implications for biology, epigenetics and clinical practice. It is not clear if mutations are in general transcribed and, if so, at what proportion to...
-
Article
Open AccessImmunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma
Tumor models are critical for our understanding of cancer and the development of cancer therapeutics. Here, we present an integrated map of the genome, transcriptome and immunome of an epithelial mouse tumor, ...
-
Book
-
Chapter
Final Words
When the idea for a book dedicated to the 70th birthday and the lifetime achievements of Professor Dr. Christoph Huber was born, we immediately considered asking authors that not only are renowned experts in t...
-
Article
The regulatory landscape for actively personalized cancer immunotherapies
-
Protocol
Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro and In Vivo Preclinical Studies
Synthetic antigen-encoding mRNA is increasingly exploited as a tool for delivery of genetic information of complete antigens into professional antigen presenting dendritic cells for HLA haplotype-independent a...
